In addition to T-lineage cells, a small proportion of hematopoietic non-T cells are present in the human postnatal thymus. However, the origin of this minor non-T cell thymic compartment is presently unknown. In this study we have analyzed the developmental potential of the earliest human intrathymic precursors, characterized as CD34 § cells expressing intermediate levels of CD44. We show that these CD34 § CD44 jut thymocytes cultured with interleukin 7 were able to develop simultaneously into both T-and non-T (monocytes and dendritic cells) -lineage cells. Both developmental pathways progress through a CDI+CD4 § intermediate stage, currently believed to be the immediate precursor of double positive thymocytes. However, separate progenitors for either T or non-T cells could be characterized within CDI+CD4 + thymocytes by their opposite expression of CD44. Downregulated levels of CD44 identified CD1 § CD4 + T-lineage precursors, whereas CD44 upregulation occurred on CDI+CD4 § intermediates that later differentiated into non-T cells. Therefore, commitment of human early intrathymic precursors to either T or non-T cell lineages can be traced by the differential expression of the CD44 receptor.
ne marrow-derived hematopoietic precursors homing the human thymus have been identified as CD3-CD4-CDS-triple negative (TN) 1 thymocytes (1, 2). The T cell precursor potential of TN thymocytes is confined to cells that express CD34 (3), a marker of pluripotent hematopoietic stem cells (4) (5) (6) . A major question is whether these CD34 § early thymic immigrants are already fully committed to the T cell lineage, or whether they represent primitive precursors that can also give rise to the small percentage (<1%) of hematopoietic non-T cells normally present in the human postnatal thymus (7) (8) (9) (10) (11) . The last possibility is consistent with the reported presence of myeloid progenitors in immature populations of both fetal and neonatal thymocytes (1, 12, 13) . It is further supported by very recent results showing that the human fetal thymus is permissive for the development of both lymphoid and myeloid hematopoietic lineages derived from fetal liver progenitors (13) . However, direct evidence that human thymic non-T cells are derived from primitive progenitors seeding the thymus is still lacking.
In contrast, recent studies in mice have shown that the first cells in the adult thymus are able to give rise to non-T cell lineages. Early postnatal thymocytes (14) were shown to 1 Abbreviations used in tkispaper: DC, dendritic calls; DP, double positive; TN, triple negative. differentiate into T cells and dendritic cells (DC) after intrathymic injection (15) and had the capacity to form B and NKI.1 + cells in the appropriate environment (16, 17) . These data suggest that the most immature intrathymic precursors represent an intermediate stage between the multipotential stem cells in the bone marrow and later unipotential T cell-committed thymocy, tes and support their dual potential to develop into both lymphoid and nonlymphoid lineages (15) . At the present time, however, separate intrathymic precursors for these two developmental pathways remain to be identified (14) (15) (16) (17) .
Identification of the equivalent precursors in the human thymus has been hampered by the lack of in vitro assays to assess both differentiation options. Since IL-7 is the only known factor that does not disrupt the differentiation potential of early thymocytes in vitro (18, 19) , while maintaining their viability (18) (19) (20) (21) , this study was aimed at investigating the capacity of the earliest CD34 + human intrathymic precursors to develop into T and non-T cell lineages when cultured in the presence of IL-7.
Materials and Methods

Isolation of CD34 + Precursors from the Human Postnatal Thymus.
Normal human thymocytes were obtained from thymus fragments removed during corrective cardiac surgery of patients aged 1 mo to 3 yr. Intrathymic CD3-CD4-CD8-TN precursors were isolated as previously described (22) . Briefly, cells were treated with anti-CD4 (HP2/6), and -CD8 (B9.4) mAbs plus rabbit complement (Sera-Lab Ltd., Sussex, UK). Anti-CD3 was not included in this treatment to avoid the possibility of CD3 capping. After Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) centrifugation, recovered viable cells were treated with a cocktail of anti-CD4, -CD8, and -CD3 (SPV-T3b) mAbs followed by two rounds of immunomagnetic bead depletion (Dynabeads; Dynal, Oslo, Norway). In some experiments, when a high proportion of mature thymic B and NK cells was detected, depletion with anti-CD19 and -CD56 (Becton Dickinson & Co., San Jose, CA) mAbs was also performed. CD34 + cells were then purified from adherent cell-depleted TN thymocytes through positive selection with CD34-coated immunomagnetic beads (Dynal).
Immunofluorescence and Flow Cytometry. mAbs against the following antigens were used: CDla (T6-RD1), CD2 (Tll-RD1), CDllb (MO1-FITC), and CD14 (MO2-FITC) from Coulter Clone (Hialeah, FL); CD3 (Leu-4-PE) from Becton Dickinson & Co.; CD4 (Leu-3a-PE or OKT4A-FITC) from Becton Dickinson & Co. and Ortho Pharmaceuticals (Raritan, NJ), respectively; CD8 (Leu2a-FITC and OKT8-FITC) from Becton Dickinson & Co. and Ortho Pharmaceuticals, respectively; CD7 (Leu-9-FITC), CD13 (Leu-M7-PE), CD16 (Leu-llc-PE), CD19 (Leu-12-FITC), CD22 (Leu-14-PE), CD33 (Leu-M9-PE), CD34 (HPCA-2-PE or HPCA-2-FITC), CD44 (Leu-44-FITC), CD56 (Leu-19-PE), B7 (BB1), and HLA-DR (anti-HLA-DR-PE) from Becton Dickinson & Co.; CD21 (B-E5-FITC) from Serotec (Oxford, UK); and CD23 (IOB8) from Immunotech (Marseille, France). Anti-CD25 (MAR108-FITC) and -CD45 (GAP8.3-FITC) have been previously described (23) . Anti-CD40 (mAb89) was kindly provided by Dr. J. Banchereau (Schering-Plough, Dardilly, France), and anti-HLA-DP and -HLA-DQ were the kind gift of Dr. J. Bodmer (Imperial Cancer Research Fund, London, UK).
Single-and two-color immunofluorescence studies were performed as described elsewhere (23) 
Results
Antigenic Phenotype of Human CD34 + Postnatal Thymocytes.
To investigate the antigenic phenotype of the first hematopoietic precursors present in the human postnatal thymus, CD34 + cells were purified from preparations of thymocytes depleted of cells expressing CD3, CD4, or CD8 antigens (TN thymocytes). As displayed in Fig. 1 A, TN thymocytes were highly enriched (>90%) in cells showing a heterogeneous (low-to-bright) expression of the CD34 antigen. CD34 + TN thymocytes displayed a low CD45 expression, typical for early progenitor cells (6) . A 10-fold higher expression of CD45 was detected in a minor fraction (<10%) of CD34-TN thymocytes, which included mature CD7-CD22 + B cells and CD7+CD56 + NK cells ( Fig. 1 A and data not shown), normally present in the human postnatal thymus. In contrast to CD34 + hematopoietic stem cells in the bone marrow (6, 24) , intrathymic CD34 + precursors coexpressed the CD7 molecule. As described previously (3, 20) , expression of the CD1 thymic differentiation marker (3, 6) subdivided CD34 + thymocytes into two different subsets. The majority of CD34 + thymocytes (75% in this particularly experiment) coexpressed CD1, but CD34+CD1 -cells were also consistently detected. According to previous data (3), we observed that expression of CD34 on the CD1-CD34 + cells was higher than on CD1 +CD34 + thymocytes ( Fig. 1 A) . Depletion ofTN thymocyte suspensions to eliminate B and NK cells, followed by immunomagnetic selection of CD34 + thymocytes, rendered a highly enriched population of cells (0.05-0.1% of all thymocytes, >98% pure) that displayed high-surface density CD34 (Fig. 1 B) . This isolation technique was found inefficient for selecting CD34 dai thymocytes; therefore, we consistently recovered cells expressing high levels of CD34 (10-15% of total CD34 + TN thymocytes in different experiments). As shown in Fig. 1 B, these CD34 § thymocytes lacked specific markers of mature T (CD3, CD4, CD8) and myeloid (CD14, CD11b) cells. Expression of B-(CD1.9, CD22) and NK-lineage (CD56) antigens was negative as well (not shown). Positively selected CD34 + thymocytes displayed high-surface density CD7 and coexpressed CD2 molecules. However, expression of CD1 was barely detectable in a minor proportion (8% in this experiment) of CD34+CD7 § + thymocytes ( Fig. 1 B) , supporting the finding that expression of high levels of CD34 is mainly confined to CD1-thymocytes, considered to be the most immature intrathymic precursors (3). Further analysis of these postnatal CD34 + thymocytes revealed an antigenic phenotype very similar to that of CD34 § early precursors present in the fetal thymus (13) , including a variable expression of low levels of CD33 (20% in this particular experiment) and the expression of HLA-DK by most (82%) CD34 + cells (Fig. 1 B) . In addition, CD34 + thymocytes 
CD34 + CD44 int Thymic Precursors Differentiate into Two Distinct CD34-Cell Populations, One CD44~g ht, the Other CD44-, in the Presence of lL-Z
The developmental potential of early CD34 + postnatal thymocytes was analyzed by phenotypic studies performed on CD34 § cells cultured in the presence of rhlL-7. CD34 + thymocytes were shown to proliferate in an IL-7-dependent manner during the first 3-4 d of culture. Results of one representative experiment (out of three) displayed in Fig. 2 show that viable cell numbers increased about threefold over the initial 3-d culture period and was maintained from day 3 to day 6 (cell viability >99%) in the presence of IL-7. Thereafter, cellular recovery decreased steadily, although a small proportion of viable cells could be maintained for up to 2-3 wk. In contrast, cell viability dropped rapidly without IL-7. The proliferative phase of culture was accompanied by the appearance of colonies containing >50 cells/colony. Nonaggregated smaller round cells were detected as well. The size of the colonies decreased throughout culture. This was paralleled by a gradual increase in large, irregularly shaped cells within the colonies. To study the phenotypic profile of cells undergoing these morphological changes, IL-7-cultured CD34 + thymocytes were then analyzed by flow cytometry. Since differentiation of mouse CD44 + thymic progenitors into mature T cells has been shown to proceed through an intermediate CD44-stage (19), we inves-
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M~rquez et al. 6 10- tigated whether changes in CD44 expression could also define control points in the development of human CD34 § thymic precursors. As shown in Fig. 3 , no significant changes in CD34 and CD44 expression were detected during the initial (3 d) proliferating phase of culture, indicating that IL-7 is a growth factor for CD34 § CD44 int human thymocytes. From day 3 on, however, CD34 was gradually lost, suggesting progression through further developmental stages (3, 6, 24, 27) . Interestingly, the decrease in CD34 was accompanied by the segregation of CD44 int cells into two different cell populations showing opposite CD44 expression. Up-or downregulation of CD44 was evident in CD34 + cells by day 6 of culture, and resulted in the appearance of two separate subsets of CD34-cells, one CD44bas ht, the other CD44-, by day 8 (Fig. 3) . large cells by day 8 (Fig. 4) . A close correlation between CD44 expression and cell size could be established when electronic gates were placed on the small (80-90%) and large (10-20%) subsets. CD44-thymocytes were mainly small cells, whereas CD44b~g h' thymocytes were mostly large cells. Changes in CD44 expression were also accompanied by the sequential acquisition of antigens known to be expressed early during thymic T cell differentiation. As shown in Fig.  4 , CD1 was the first molecule expressed on cultured CD34 § thymocytes. At day 3 of culture, expression of CD1 was observed in 19% of CD34 + cells. Low levels of CD4 were also detected at this time on a small cell fraction (3% of total recovered cells) that coexpressed CD1, indicating that, as previously reported (3, 20) , CD1 + are the direct precursors of CD4 + thymocytes. In fact, most CD1 + cells acquired CD4 by day 6 (20% CDI+CD4 § 5% CDI+CD4 -, in this experiment), CD4 § thymocytes becoming a major population within both the small (60%) and the large (65%) cell subsets by day 8. However, a subset of CD4 + cells lacking CD1 molecules (20%) was detected exclusively within the large CD44 bright population by day 8. A similar proportion (21%) of CD44brightCD4+CD1-cells was detected by day 10, when essentially all (96%) CD44b~g at cells were CD4 § Therefore, CD44 i~t thymocytes progressed to more mature CD44 b~ight or CD44-cells through a CDI+CD4 + intermediate stage. However, high levels of both CD1 and CD4 molecules were expressed on CD44b~ig ht cells, whereas intermediate expression levels of both antigens were consistently found in the CD44-population.
Both CD44-and CD44~g ht Subpopulations
CD44~ he but Not CD44-Progeny Derived from CD34 + Precursors Comprise a Mixed Population of Monocytic Cells and Dendritic Cells.
To determine the nature of both the large CD44bag ht and the small CD44-populations derived from CD34 + thymic precursors, cells were stained with a panel of mAbs against distinct lymphoid and myeloid-associated markers ( Fig. 5 and Table 1 ). Both the small and the large cell subsets were shown to keep CD2 expression at variable levels, indicating that they were derived from intrathymic precursors rather than from contaminating peripheral blood stem cells (6, 24) . However, each population displayed radically distinct phenotypic profiles (Fig. 5) . Small CD44-thymocytes were characterized as T-lineage cells by several criteria: (a) they retained a high CD7 expression; (b) they lacked B call-, NK cell-(not shown), and myeloid-related antigens, as well as HLA class II molecules; and (c) as expected for T cell precursors, they developed into CD4 + CD8 + double positive (DP) thymocytes through a CDI+CD4 + transitional subset (Fig. 5) . These DP thymocytes expressed cytoplasmic but not membrane CD3. (not shown), suggesting that they represent the immediate precursors of surface CD3 + DP thymocytes. This sequence of maturation events corresponds to that found in vivo for both postnatal and fetal thymic precursors differentiating toward mature T cells (3, 20, 27) . However, no transition to CD3 + T cells could be detected under our culture conditions, since cell viability of CD3-DP thymocytes dropped rapidly from day 8 to day 10. This suggests that additional signals to those provided by IL-7, most likely involving the participation of the thymic stromal 479 Mfirquez et al. Log. Fluorescence Intensity (a.u.) components, are required for terminal differentiation of T cell-committed precursors. In contrast to CD44-thymocytes, large CD44bns h' cells lacked the CD8 T cell molecule but expressed very high levels of CD4 (10-fold higher than CD44-DP thymocytes) (Fig.  5) . They expressed low CD7 levels, suggesting that CD7 was downregulated throughout culture. Most of these cells showed high levels of the myeloid-related antigens CDllb, CD13, and CD33, as well as of HLA-DK, -DP, and -DQ class II molecules, and many of them were CD14 § (Fig. 5 and Table  1 ). This phenotypic pattern closely resembles that recently found on myelomonocytic cells derived from CD34 § fetal liver precursors in a human fetal thymic organ culture system (13) . However, >50% of CD44 b~gh' cells shown to express myeloid-related markers also displayed a heterogeneous expression of the CD23, CD40, and B7 (CD80) B-lineage markers (Table 1) . Interestingly, variable levels of these molecules have previously been reported in different studies (28) (29) (30) to be expressed on peripheral Langerhans/DC. Cells displaying this phenotypic profile could be maintained in culture for up to 2-3 wk. Morphologic studies of in vitro-derived CD44bng ht large cells revealed a mixed population of adherent and nonadherent morphology of macrophages and cells displaying dendritic processes. Further examination of these cells by scanning electron microscopy revealed a typical dendritic morphology (8, 28) , with a stellate shape and dendritic projections (Fig. 6) . Finally, functional assays demonstrated the APC capacity of the CD44b~ ht cells by showing that they were potent stimulators of the allogeneic MLP-, (29) . Proliferation of allogeneic peripheral T cells (2 x 105) was increased 40-fold by 104 CD44b~ ht stimulators (Fig. 7) . Therefore, based on morphologic, phenotypic, and functional criteria (8, (28) (29) (30) , we can conclude that CD44bng h~ progeny derived from CD34 + precursors includes DC as well as monocytic cells. These data provide evidence that CD34 § thymocytes are able to differentiate into non-T cell lineages in the presence of IL-7, suggesting that lymphoid as well as nonlymphoid cells can be newly generated in the human thymus from intrathymic precursors.
Discussion
Current in vitro experimental systems for hematopoiesis are hampered by the fact that lineage programs undertaken by multipotential precursors are influenced by the specific growth factors to which they are exposed. However, studies in mice have shown that hematopoietic precursors cultured with IL-7 retain their intrinsic developmental potential (18, 19) . In fact, IL-7 appears to be an important regulator of the growth of both T-and B-lymphoid progenitors, (18) (19) (20) (21) and, recently, a novel role for IL-7 in early myelopoiesis has been reported (31) . In this study, we have analyzed the precursor potential of CD34 + human postnatal thymocytes, which are known to represent the earliest intrathymic precursors, when cultured in the presence of IL-7. Our results revealed the capacity of CD34 + thymocytes to proliferate in response to and develop simultaneously into T-lineage cells, monocytic cells, and DC. Therefore, in addition to its reported involvement in early lymphopoiesis and myelopoiesis (18) (19) (20) (21) 31) , these data suggest a novel role of IL-7 in the development of DC.
We have shown that IL-7 was able to induce a marked proliferation of CD34 + thymocytes (which were >98% pure upon reanalysis) during the initial 3 d of culture. As previously reported (20) , IL-7 was also able to maintain the viability of CD34 + thymocytes at later periods of culture. Phenotypic studies revealed no significant antigenic changes during the proliferating phase of culture, indicating that cells capable of responding to IL-7 were included within the CD34 § thymic subset. From day 3 on, however, IL-7-cultured cells sequentially acquired the CD1 and CD4 antigens and either myeloid/DC-lineage markers or the CD8 T cell molecule, and CD34 was concurrently downregulated. It is thus unlikely that all these phenotypic changes could be explained by a selective death of CD34 + thymocytes, or by the outgrowth (from day 3 on of culture) of a minor contaminating CD34-population of already differentiated cells. Supporting our findings, it has been previously shown that proliferation induced by IL-7, as well as differentiation into CD4+CD8 + DP thymocytes, is restricted to the CD34 § thymic subset (3, 32) . However, no myeloid or DC precursor potential was detected in a previous study by Schmitt et al. (32) on ex vivo-isolated CD34 § thymocytes cultured in the presence of myeloid growth factors. These contradictory results may be explained by the heterogeneity of the CD34 + thymic subset. About 75% of the CD34 + thymocytes reported by Schmitt et al. expressed CD1, and 30% of them were CD4 +, whereas our preparations were highly enriched in CD34bnghtCD1-CD4 -cells. These data suggest that the myeloid/DC precursor potential of CD34 + thymocytes resides in the CD1-subset, while most CD34 + CD1 + thymocytes may represent T cell-committed precursors. Similarly, it has been recently shown that bipotential T/NK cell progenitors present in the human fetal thymus are confined to the CD1-subset of CD34 bright thymocytes (33) . It is also possible that IL-7 [which was omitted in the differentiation assay reported by Schmitt et al. (32) ] is required to induce the proliferation and maintain the differentiation potential of primitive myeloid/DC intrathymic precursors, whereas specific growth factors may be required to drive their terminal differentiation. This concurs with the observation that IL-7 potently enhances the myelopoietic potential of bone marrow hematopoietic stem cells, whereas it has no effect on committed myeloid progenitors (31) . Supporting this possibility, we have observed that the simultaneous addition of IL-7 and GM-CSF to our cultures greatly improved both the proportion and survival of DC, as well as of a CD1-subset of CD44b~ightCD4 + CDllb +DR. + cells, likely representing myelomonocytic precursors (not shown).
Our results provide evidence for a dual potential of human CD34 + thymic precursors to develop into either T or non-T (monocytes and DC) cell lineages, but they do not preclude that separate precursors, one for each hematopoietic lineage, may be included within the CD34 + thymic population. Therefore, we cannot yet conclude that the CD34 + thymic subset displays pluripotent hematopoietic activity. Confirmation of this possibility must await the development of a suitable clonal assay. In our culture conditions, both DC as well as T-lineage cells were shown to develop through a CD1 + CD4 + intermediate stage. However, separate precursors for either the T or the DC lineages could be identified at this early developmental stage by their differential expression of both CD1 and CD4 markers (CDlintCD4 int or CD1 bright CD4brig ht for T and DC precursors, respectively). In agreement with our results, Sotzik et al. (9) have recently reported a bright CD4 expression on ex vivo-isolated thymic DC. Intrathymic DC, however, did not express CD1, suggesting that this molecule is lost in more mature differentiation stages in the DC lineage. We have observed that CD34 § thymoeytes can also give rise to macrophages, although the existence of a CDI+CD4 + intermediate stage in the development of this myeloid lineage remains to be clarified. It can be speculated that, as proposed for bone marrow-derived macrophages and DC (34), a common bipotential progenitor for these two cell lineages exists in the human thymus.
The simultaneous development of both lymphoid (T cells) and nonlymphoid (monocytes and DC) lineages from CD34 § thymic progenitors allowed us to identify distinctive maturation events associated with lineage choice in the thymus. We have shown that commitment to each alternative developmental pathway can be traced by the differential expression of CD44. Therefore, separate CD1 +CD4 + precursors for either DC and T cells can be characterized, respectively, as CD44brig ht or CD44-cells. The observation that both cell populations do exist in the human postnatal thymus (9, and our unpublished results) at a ratio (1-2:10) similar to that found in our in vitro assays provides additional support for their physiological relevance in vivo. Indeed, previous results in mice have shown that transition from CD44 § to CD44-in the thymus is an obligatory step during early T cell differentiation (13) . Whether CD44 expression may also be used to identify lymphoid precursors able to give rise to the B and/or NK cell intrathymic compartments is currently under investigation.
In light of these studies, regulation of CD44 expression may be envisaged as an early consequence of the developmental program undertaken by intrathymic precursors. Alternatively, CD44 regulation may play a prominent role in lineage commitment decisions of putative multipotential hematopoietic precursors. Changes in CD44 expression during early thymic development may thus be related to differences in the adhesion requirements to stromal components of distinct thymic precursors and/or the migration patterns of their respective progenies. Finally, the reported expression of CD4 molecules along the differentiation pathway of both T cells and thymic APC (macrophages and DC) has obvious implications for the immunopathological consequences of HIV infection (35) , since either viral carriage by thymic APC or their infection would lead to the induction of tolerance in those T cell clones specific for viral antigens, thus precluding the induction of protective immunity.
